Pharmacology Daily

WE CHATTED WITH DR. POPE ABOUT ANABOLIC STEROIDS

DR. JOSEPH DISCUSSES THE LIMITATIONS OF GENETIC STUDIES

PAXLOVID AND COVID 19 STUDY

A COMBINATION OF TWO MEDICATIONS SHOW PROMISE IN HELPING WITH ALCOHOL USE DISORDER

PRENATAL CANNABIS USE AND INCREASED RISK FOR ADHD AND AUTISM SPECTRUM DISORDER

RISK OF AUTISM AFTER PRENATAL EXPOSURE TO VALPROATE

METH RELATED CARDIO MYOPATHY

ACCIDENTAL EXPOSURE TO FENTANYL PATCHES CONTINUE TO BE DEADLY TO CHILDREN

AN INTERESTING STUDY ON PROTON PUMP INHIBITORS AND PULMONARY TB

DR. HASKINS DISCUSSES FRAUD IN THE MEDICAL FIELD1

HORMONAL CONTRACEPTION AND ADHD

WE CHAT WITH DR.PARIS AND HIS BOOK ON TRAUMA

GENETIC TESTING FOR PREDICTING ADVERSEDRUG REACTIONS DOESNT SHOW PROMISE

GABAPENTIN AND ITS USE FOR TREATING ALCOHOL USE DISORDER1

ARE BUPRENORPHINE DOSES TOO LOW

FDA TOOK LOOK AT NEW DRUG FOR SCHIZOPHRENIA

REL-1017 SHOWS EFFICACY FOR MAJOR DEPRESSIVE DISORDER IN PHASE 3

DOES EXPECTANCY BIAS PLAY A ROLE IN THE EFFICACY OF KETAMINE

VYVNANSE GENERIC APPROVED BY FDA AND LEVODOPA CARBIDOPA COMBO FOR PARKINSONS

OTC NALOXONE AND NEW NASAL SPRAY MEDICATION FOR SOCIAL ANXIETY DISORDER